Levetiracetam - Revision history

MDElliottMD: parser-claude: Levetiracetam MedTemplate refill, Top 300 stub upgrade

2026-05-23T06:57:45Z

parser-claude: Levetiracetam MedTemplate refill, Top 300 stub upgrade

← Older revision		Revision as of 06:57, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Levetiracetam		\| generic = Levetiracetam
	\| brand = Keppra		\| brand = Keppra (IR), Keppra XR, Spritam (3D-printed orally disintegrating), Roweepra
	\| structure =		\| structure =
	\| classes = Anticonvulsant		\| classes = [[:Category:Anticonvulsants\|Anticonvulsant]], [[:Category:SV2A ligands\|Synaptic vesicle protein 2A (SV2A) ligand]]
	\| ~~mechanism =~~ SV2A ligand		\| uses = <vote slug="partial-seizures-monotherapy-use">Partial-onset seizures (FDA, monotherapy and adjunct)</vote>, <vote slug="juvenile-myoclonic-epilepsy-use">Myoclonic seizures of juvenile myoclonic epilepsy (FDA, adjunct)</vote>, <vote slug="generalized-tonic-clonic-use">Primary generalized tonic-clonic seizures of idiopathic generalized epilepsy (FDA, adjunct)</vote>, <vote slug="status-epilepticus-second-line-use">Status epilepticus (off-label, second-line after benzodiazepine)</vote>
	\| uses =		\| starting_dose = Adult: 500 mg PO BID, titrate by 1000 mg/day every 2 weeks. Pediatric: 10-20 mg/kg/day divided BID, weight-titrated
	\| starting_dose =		\| preparations = IR tablets 250, 500, 750, 1000 mg; XR tablets 500, 750 mg; oral solution 100 mg/mL; injection 100 mg/mL; Spritam ODT 250, 500, 750, 1000 mg
	\| preparations =		\| fda_max = 3000 mg/day
	\| fda_max =		\| pill_id =
	\| routes =		\| routes = Oral, intravenous
	\| onset =		\| onset = Anticonvulsant effect within days at therapeutic plasma level; rapid titration possible
	\| duration =		\| duration = BID dosing (IR); once-daily (XR)
	\| halflife =		\| halflife = 6-8 hours<ref name="keppra-label">FDA Prescribing Information, Keppra (levetiracetam), UCB, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021035s101lbl.pdf</ref>
	~~\| bioavailability =~~		\| bioavailability = ~100% (oral)<ref name="keppra-label" />
	~~\| pregnancy~~ =		\| pregnancy = '''Considered one of the safest anticonvulsants in pregnancy''', with reassuring monotherapy registry data comparable to lamotrigine and in sharp contrast to valproate, topiramate, and carbamazepine<ref name="keppra-label" />
	~~\| legal~~ =		\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Not a controlled substance<ref name="keppra-label" />
	\| ~~intro~~ =		\| mechanism = <vote slug="levetiracetam-mech-claim">Binds the synaptic vesicle protein 2A (SV2A), modulating presynaptic neurotransmitter release through a mechanism distinct from sodium channel, calcium channel, GABA, and glutamate receptor mechanisms of older anticonvulsants. The result is reduced neuronal hyperexcitability with minimal sedation or cognitive impact compared to most other anticonvulsants.</vote> The marquee adverse-effect concern is '''behavioral and psychiatric''': irritability, depression, agitation, anxiety, and suicidal ideation, with the AED-class FDA suicidality warning particularly associated with this agent. Pyridoxine (vitamin B6) supplementation may mitigate these in some patients. Renally eliminated; dose adjustment by creatinine clearance is required<ref name="keppra-label" />.
	~~\| pharmacokinetics~~ =
	\| ~~pharmacodynamics~~ =
	~~\| indications~~ =
	\| ~~dosing~~ =
	\| ~~effects~~ =
	~~\| interactions = <pharmaInteractions~~/>
	\| ~~pregnancy_details =~~
	~~\| monitoring~~ =
	~~\| counseling~~ =
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references~~ =
	}}		}}

	[[Category:~~Antiepileptics~~]]		== References ==
			<references />

			[[Category:Anticonvulsants]]
	[[Category:SV2A ligands]]		[[Category:SV2A ligands]]

MDElliottMD: Category taxonomy ship: retag Anticonvulsants -> Antiepileptics

2026-05-22T00:36:48Z

Category taxonomy ship: retag Anticonvulsants -> Antiepileptics

← Older revision		Revision as of 00:36, 22 May 2026
Line 31:		Line 31:
	}}		}}

	[[Category:~~Anticonvulsants~~]]		[[Category:Antiepileptics]]
	[[Category:SV2A ligands]]		[[Category:SV2A ligands]]

MDElliottMD: Dedupe migration per interface-claude 2026-05-20: Anticonvulsants / Antiepileptics merged into canonical Anticonvulsants. Member retagged.

2026-05-19T18:00:14Z

Dedupe migration per interface-claude 2026-05-20: Anticonvulsants / Antiepileptics merged into canonical Anticonvulsants. Member retagged.

← Older revision		Revision as of 18:00, 19 May 2026
Line 31:		Line 31:
	}}		}}


	~~[[Category:Anticonvulsants / Antiepileptics]]~~
	[[Category:Anticonvulsants]]		[[Category:Anticonvulsants]]
	[[Category:SV2A ligands]]		[[Category:SV2A ligands]]

MDElliottMD: Comprehensive categorization: +SV2A ligands

2026-05-15T18:42:20Z

Comprehensive categorization: +SV2A ligands

← Older revision		Revision as of 18:42, 15 May 2026
Line 34:		Line 34:
	[[Category:Anticonvulsants / Antiepileptics]]		[[Category:Anticonvulsants / Antiepileptics]]
	[[Category:Anticonvulsants]]		[[Category:Anticonvulsants]]
			[[Category:SV2A ligands]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:07:03Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:07, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Anticonvulsants / Antiepileptics]]
	[[Category:Anticonvulsants]]		[[Category:Anticonvulsants]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:30:56Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:30, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:38Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:51Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Anticonvulsants]]		[[Category:Anticonvulsants]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Levetiracetam
+| generic            = Levetiracetam
-| brand             = Keppra
+| brand              = Keppra
-| classes           = Anticonvulsant
+| structure          =
-| mechanism         = SV2A ligand
+| classes            = Anticonvulsant
 }}
 [[Category:Anticonvulsants]]

MDElliottMD: Auto-created stub

2026-05-13T00:00:00Z

Auto-created stub

New page

{{MedTemplate
| generic = Levetiracetam
| brand = Keppra
| classes = Anticonvulsant
| mechanism = SV2A ligand
}}
[[Category:Anticonvulsants]]